• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

CAR-T

A series of dice with a bag on them illustrating cost cuts
Biotech

Cellectis will shed 70% of workforce as part of in vivo pivot

Cellectis’ pivot from allogeneic CAR-Ts to in vivo therapies is set to come at the expense of 70% of its workforce.
James Waldron Nov 13, 2026 9:18am
T-cells cancer cells CAR-T lymphocytes

Generate sees ‘huge opportunity’ using Claude to improve CAR-Ts

Nov 6, 2026 10:02am
Bristol Myers Squibb booth at AACR 2026

BMS sheds light on patient death in CAR-T trial

Oct 26, 2026 7:00am
Schinecker

Roche CEO has ‘absolutely not’ changed view on Poseida buyout

Oct 22, 2026 4:16am
A ballpoint pen rests on top of a stack of documents ready for signing

Rebranded Galapagos finally finds buyer for cell therapies

Oct 15, 2026 4:09am
Caribou antlers against the sky

Caribou’s ‘heartbreaking’ call to lay off staff, halt pipeline

Oct 7, 2026 5:00am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings